Gull, Nicole
Jones, Michelle R.
Peng, Pei-Chen
Coetzee, Simon G.
Silva, Tiago C.
Plummer, Jasmine T.
Reyes, Alberto Luiz P.
Davis, Brian D.
Chen, Stephanie S.
Lawrenson, Kate
Lester, Jenny
Walsh, Christine
Rimel, Bobbie J.
Li, Andrew J.
Cass, Ilana
Berg, Yonatan
Govindavari, John-Paul B.
Rutgers, Joanna K. L.
Berman, Benjamin P.
Karlan, Beth Y.
Gayther, Simon A.
Funding for this research was provided by:
Cedars-Sinai Medical Center Precision Healthy Initiative
NIH/NCI (R01CA211575)
National Institutes of Health (U01CA184826, U01CA184826)
Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Developmental Funds
Ovarian Cancer Research Alliance Liz Tilberis Early Career Award (599175)
Ovarian Cancer Research Alliance Program Project Development Award (373356)
Research Scholar’s Grant from the American Cancer Society (134005)
National Cancer Institute (K99CA256519)
Generous donation from the Barth Family
Article History
Received: 29 December 2021
Accepted: 13 July 2022
First Online: 27 July 2022
Declarations
:
: Informed consent was obtained from all twenty-eight women included in this study, agreeing to provide fresh-frozen high-grade serous ovarian cancer specimens and DNA, as well as detailed clinical data including clinical genetic testing results, dates of original diagnosis and each subsequent recurrence, treatments administered throughout their disease course, operative and pathology reports, and other clinicopathologic variables including other cancer diagnoses and comorbidities. All women were diagnosed with high grade serous adenocarcinoma. Specimens were all identified in the Cedars-Sinai Medical Center Women’s Cancer Program Biorepository under Institutional Review Board Protocol #0901.
: Not applicable.
: The authors declare that they have no competing interests.